YCBD cbdMD Corp Return on Gross Profit

Official company branding of cbdmd.com (YCBD)

The potential of cbdMD, Inc. (YCBD) is based on THC-free patents and raw material purity control, which confirms production margins: the current level is approximately 52.80. However, revenue volatility is driven by advertising bans and customer loyalty. Further risk stems from the fragmentation of the US CBD market, forcing the business to optimize retail networks amid declining consumer demand.

YCBD - cbdMD Corp Return on Gross Profit over the range 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company cbdMD, Inc. (YCBD)

- stock quotes and analyst forecast:
- market capitalization data:
Fundamental valuation:YCBD, cbdMD
Mass-produced product of cbdMD Corp

Gross margin measures production efficiency by determining the portion of revenue remaining after direct product creation costs. For cbdMD, Inc. (YCBD), gross margin profitability reflects the brand's ability to monetize cannabidiol-based product sales under current cost optimization. Steady growth in this metric confirms the business's operational resilience, while a decline signals a risk of falling profits.

Key competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin ENTX (Entera Bio)|Gross Sales Margin MindWalk Therapeutics|ABVC: Return on Gross Profit|CPIX - Gross Margin|QNTM (Quantum BioPharma) - Return on Gross Profit|Gross Profitability Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Gross Margin|Gross Margin ranitherapeutics.com|Gross Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Gross Return on Sales|lexariabioscience.com - Return on Gross Profit|Gross Margin Pulmatrix Inc PULM|Pheton Holdings - Gross Margin|Gross Profitability Margin APM|Lyra Therapeutics, Inc. (LYRA) - Gross Profitability|Gross Profit Margin Impact BioMedical, Inc. (IBO)|Gross Profitability TNF Pharma|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin